HSGX - Histogenics Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1940
-0.0061 (-3.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.2001
Open0.2000
Bid0.1800 x 3100
Ask0.1934 x 1200
Day's Range0.1885 - 0.2046
52 Week Range0.0800 - 3.0500
Volume5,821,851
Avg. Volume10,306,558
Market Cap18.352M
Beta (3Y Monthly)4.77
PE Ratio (TTM)N/A
EPS (TTM)-0.7850
Earnings DateMar 15, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • Histogenics News: Why Did HSGX Stock Soar Today?
    InvestorPlace11 days ago

    Histogenics News: Why Did HSGX Stock Soar Today?

    Histogenics (NASDAQ:HSGX) stock went gangbusters on Monday as the company has reportedly inked a deal with another business in the industry.Source: FlickrPennsylvania-based Ocugen is a developer of gene therapies and other biologics designed to treat rare eye diseases, and the company has agreed to a reverse merger with struggling Massachusetts-based business Histogenics. Ocugen was founded by Pfizer veteran Shankar Musunuri and University of Colorado professor Uday Kompella.The move will see Histogenics shareholders collectively hold about 10% of the new, combined company, which will include only Ocugen's lean team. However, before the former company's executives depart from the business, they will try to sell NeoCart, which is its regenerative treatment designed to treat knee cartilages.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe program was dropped by Histogenics in December as the Food and Drug Administration asked to see more data before accepting a BLA for review. Meanwhile, Ocugen's last financing round was reportedly a $7.5 million Series B closed in 2017, which added to its $6 million in Series A cash.Ocugen makes its bread and butter from drugs that arose from two platforms that were licensed from harvard's Schepens Eye Research Institute of Massachusetts Eye and Ear. One of these formulates therapies known as a nanoemulsion, which is reportedly more durable and effective than your run-of-the-mill eye drops, while the other is geared to deliver nuclear hormone receptor that goes into the retina.HSGX stock is up about 56% on Monday, while gaining another 9.3% after the bell. More From InvestorPlace * The Elite 8 Stocks to Buy for Massive Outperformance * 15 Stocks to Buy Leading the Financial Charge * 8 Best Stocks to Buy for an April Rally Compare Brokers The post Histogenics News: Why Did HSGX Stock Soar Today? appeared first on InvestorPlace.

  • Benzinga12 days ago

    Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

    The deal is a stock-for-stock transaction. Ocugen has a pipeline of opthalmology programs that include a modifier gene therapy platform, including OCU400 for the treatment of NR2E3-mutation associated retinal degenerative diseases.

  • American City Business Journals12 days ago

    Histogenics to serve as shell for Pennsylvania biotech in reverse-merger

    Beleaguered cell therapy firm Histogenics Corp. has found a way to avoid bankruptcy or shutting down, announcing Monday that it will be absorbed by a Pennsylvania biopharma.

  • Malvern gene therapy developer to acquire publicly traded Boston company
    American City Business Journals12 days ago

    Malvern gene therapy developer to acquire publicly traded Boston company

    The combined company will be based in Malvern and have a focus on rare and underserved eye diseases.

  • GlobeNewswire12 days ago

    Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

    Histogenics Corporation (HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today jointly announced that they have entered into a definitive merger agreement under which the stockholders of Ocugen will become the majority owners of Histogenics’ outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly-traded, clinical-stage biopharmaceutical company operating under the Ocugen name.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of HSGX earnings conference call or presentation 9-Nov-17 1:30pm GMT

    Q3 2017 Histogenics Corp Earnings Call

  • ACCESSWIRE2 months ago

    Biotech Bounce Just Getting Started

    HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers ...

  • GlobeNewswire2 months ago

    Jonathan Lieber Joins Danforth Advisors as Managing Director

    Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and public life science companies, today announced the appointment of Jonathan Lieber as Managing Director. With over 25 years of life science experience as a CFO and investment banker, Jon brings deep expertise to the role in service of clients at all stages of growth. “We hold ourselves to the highest standards of talent in the business, and Jon is no exception.

  • ACCESSWIRE3 months ago

    Biotech Stocks on the Rise

    HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are ...

  • Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?
    Zacks3 months ago

    Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?

    Is (HSGX) Outperforming Other Medical Stocks This Year?

  • ACCESSWIRE3 months ago

    Best Ways to Play Biotech Rally

    HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...

  • ACCESSWIRE3 months ago

    The Next Big Biotech Breakout

    HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks To Watch On Friday (1/4/19)

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.

  • GlobeNewswire4 months ago

    Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway

    WALTHAM, Mass., Dec. 21, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the.

  • GlobeNewswire5 months ago

    Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Nov. 29, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.

  • GlobeNewswire5 months ago

    New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Cell therapy biotech Vericel eyes $2B knee repair market
    American City Business Journals5 months ago

    Cell therapy biotech Vericel eyes $2B knee repair market

    While a competitor stumbles, Cambridge-based cell therapy biotech Vericel Corp. recently saw its share hit a new high after the company announced that its knee cartilage regeneration product could help far more patients than originally thought.

  • Associated Press5 months ago

    Histogenics: 3Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...

  • GlobeNewswire5 months ago

    Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

    WALTHAM, Mass., Nov. 08, 2018 -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to.

  • GlobeNewswire6 months ago

    Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Nov. 01, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.

  • ACCESSWIRE6 months ago

    What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price

    NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX) is a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. On September 5, 2018 HSGX announced that its Phase III clinical trial did not meet one of its primary endpoints, a measurement of pain and knee function after a year compared to microfracture surgery.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.